Coloplast A/S (CLPBY)
| Market Cap | 17.49B -31.8% |
| Revenue (ttm) | 4.38B +1.6% |
| Net Income | 627.11M -18.3% |
| EPS | 2.78 -18.4% |
| Shares Out | n/a |
| PE Ratio | 27.90 |
| Forward PE | 18.88 |
| Dividend | 0.22 (2.76%) |
| Ex-Dividend Date | Dec 8, 2025 |
| Volume | 100 |
| Average Volume | 405,549 |
| Open | 7.71 |
| Previous Close | 7.77 |
| Day's Range | 7.69 - 7.77 |
| 52-Week Range | 7.62 - 11.44 |
| Beta | 0.59 |
| RSI | 32.22 |
| Earnings Date | Feb 6, 2026 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories ... [Read more]
Financial Performance
In fiscal year 2025, Coloplast's revenue was 27.87 billion, an increase of 3.12% compared to the previous year's 27.03 billion. Earnings were 3.64 billion, a decrease of -28.03%.
Financial numbers in DKK Financial StatementsNews
Coloplast A/S reports Q1 results
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q1 2026 Earnings Call February 6, 2026 5:00 AM ESTCompany ParticipantsLars Rasmussen - Interim CEO & PresidentAnders...
Coloplast AS (CLPBF) Q1 2026 Earnings Call Highlights: Strong Organic Growth Amid Market Challenges
Coloplast AS (CLPBF) Q1 2026 Earnings Call Highlights: Strong Organic Growth Amid Market Challenges
Coloplast A/S 2026 Q1 - Results - Earnings Call Presentation
2026-02-06. The following slide deck was published by Coloplast A/S in conjunction with their 2026 Q1 earnings call.
Q1 2026 Coloplast A/S Earnings Call Transcript
Q1 2026 Coloplast A/S Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%...
Coloplast A/S - Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%...
Earnings Preview: Coloplast
Coloplast (OTC: CLPBY) is set to give its latest quarterly earnings report on Friday, 2026-02-06. Here's what investors need to know before the announcement. Analysts estimate that Coloplast will rep...
CLPBY vs. PEN: Which Stock Is the Better Value Option?
CLPBY vs. PEN: Which Stock Is the Better Value Option?
Coloplast - Premium Valuation And Pedestrian Results Have Been A Bad Mix
Coloplast (CLPBY) struggles with misses, CEO search and execution risks, but U.S./EM growth offers upside.
Coloplast announces changes to Executive Leadership Team
Today, Coloplast is announcing changes to the company's Executive Leadership Team (ELT). The changes relate to the company's Interventional Urology business as well as the global People & Culture func...
Coloplast A/S (CLPBY) Shareholder/Analyst Call - Slideshow
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S (OTCPK:CLPBY) Shareholder/Analyst Call December 4, 2025 9:30 AM ESTCompany ParticipantsJette Nygaard-AndersenLars Rasmussen - Interim CEO...
Coloplast A/S - Decisions at the Annual General Meeting 2025
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of y...
Coloplast A/S - Notice of Annual General Meeting 2025
Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the...
Coloplast A/S (CLPBY) Presents at Fiscal Year 2024/25 CPH roadshow hosted - Slideshow
Coloplast A/S (CLPBY) Q4 2025 Earnings Call Transcript
Coloplast Finance B.V. - Annual Report, 2024/25
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Coloplast A/S 2025 Q4 - Results - Earnings Call Presentation
2025-11-04. The following slide deck was published by Coloplast A/S in conjunction with their 2025 Q4 earnings call.
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.
After A 50% Decline, Coloplast Might Finally Be Worth Buying
Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic m...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET
Tuesday, 4 November 2025 at 11:00 - 12:00am CET In connection with the publication of Coloplast's interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will h...
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Announcement no. 09/2025Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today i...
Coloplast A/S - Financial Calendar 2025-26
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://www.coloplast.com/investor-relations/events-calendar/ Kind regards,Investor RelationsC...